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SUPPORTING INFORMATION New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins
Loretta Lazzarato, 1 Konstantin Chegaev, 1 Elisabetta Marini, 1 Barbara Rolando, 1 Emily Borretto, 1 Stefano Guglielmo, 1 Sony Joseph, 1 Antonella Di Stilo, 1 Roberta Fruttero, 1 Alberto Gasco, and chloromethylchloroformate (0.25 mL, 2.7 mmol) in dry CH 2 Cl 2 (15 mL), stirred at -15 °C, a solution of Py (0.22 mL, 2.7 mmol) in dry CH 2 Cl 2 (10 mL) was added dropwise. At the end of the addition the ice-salt bath was removed and the reaction mixture was allowed to reach room temperature.
After 15 min the solvent was removed and obtained oil was purified by flash chromatography.
Chromatographic eluents and yields of the products were as follow. 11 (0.44 g; 1.20 mmol) was dissolved in MeOH (15 mL) and a catalytic amount of PPTS was added.
Chloromethyl-3-nitrooxypropyl carbonate (8a
5-(4-
The resulting mixture was heated at 55°C for 2 h, then concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/acetone 6/4 v/v) to give a reddish solid, which was recrystallized from EtOH to give the title compound as a yellowish-orange solid; yield 40 %; m.p. 117.5 General procedure for the preparation of 16a and 16b. SO 2 Cl 2 (0.88 mL, 10.9 mmol) was added dropwise to 14 (3.24 g, 10.9 mmol) stirred at 0 °C. The mixture was allowed to reach room temperature and stirred for 1 hour. Then the reaction mixture was concentrated under reduced pressure to give 15 as colourless oil that was used in the next synthetic step without further purification.
°C (from EtOH
To a solution of 15 (0.85 g, 3.1 mmol) in CH 2 Cl 2 (30 mL), stirred at -15 °C, a solution of the appropriate hydroxy derivative (2.6 mmol) and N-methylmorpholine (0.31 mL, 2.6 mmol) in CH 2 Cl 2 (30 mL) was added dropwise. The reaction mixture was stirred for 1 hour at -15 °C, then for 24 hours at room temperature, then was poured in H 2 O (20 mL) and extracted with CH 2 Cl 2 (3 × 20 mL). The combined organic layers were washed with brine, dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography. Chromatographic eluents and yields of the products were as follow. Evaluation of stability in buffered solutions and in human serum. 
((4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenoxy)carbonyloxy)methyl 2-acetoxybenzoate (16a
Hydrolysis in acidic medium (pH 1.0) and in phosphate buffer (pH 7.4).
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The reverse-phase HPLC procedure allowed separation and quantitation of the remaining compound and of the products of hydrolysis (aspirin, salicylic acid, salicylate and hydroxy derivatives bearing NOdonor or H 2 S-donor moieties). HPLC analyses were performed with a HP 1100 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a membrane degasser (G1379A), a diode-array detector (DAD) (model G1315B) integrated in the HP1100 system. Data analysis was done using a HP ChemStation system (Agilent Technologies). The injection volume was 20 L (Rheodyne, Cotati, CA). The analytical column was a Nucleosil 100-5C18 Nautilus 
Inhibition of Platelet Aggregation in vitro.
Venous blood samples were obtained from healthy volunteers who had not taken any drug for at least two weeks. Volunteers, who were treated according to Helsinki protocol for biomedical experimentation, gave their informed consent to the use of blood samples for research purposes. Platelet rich plasma (PRP) was prepared by centrifugation of citrated blood at 210 g for 20 min. Aliquots (500 L) of PRP were added into aggregometer (Chrono-log 4902D) cuvettes and aggregation was recorded as increased light transmission under continuous stirring (1000 rpm) at 37 °C for 10 min after addition of the stimulus. Collagen at submaximal concentration (0.8-1.5 g/mL) was used as a platelet activator in PRP. Compounds under study were preincubated with PRP 10 min before addition of the stimulus (collagen). Vehicle alone (0.5% DMSO) added to PRP did not affect platelet function in control samples. At least 5 experiments for each compound were performed.
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The antiaggregatory activity of tested compounds is evaluated as % inhibition of platelet aggregation compared to control samples. For most active compounds IC 50 values could be calculated by non-linear regression analysis, otherwise % inhibition at maximal concentration tested (300 μM) is reported.
Vasodilator Activities.
Thoracic aortas were isolated from male Wistar rats weighing 180 -200 g. As few animals as possible were used. The purposes and the protocols of our studies have been approved by the Ministero della Salute, Rome, Italy. The endothelium was removed, the vessels were cut helically and four-six strips 
